Overview Angiotensin II in Liver Transplantation (AngLT-1): a randomized clinical trial Vasoplegia is a life-threatening syndrome that can arise during liver transplantation. It consists of low blood pressure due to low systemic vascular resistance that is highly resistant to standard drugs such as catecholamines. The AngLT-1 trial (NCT04901169) aims to test the recently FDA-approved drug, angiotensin II, for safety and efficacy as a second-line vasopressor agent during liver transplantation. AngLT-1 is a prospective, double-blind, randomized, placebo-controlled trial. Read the full protocol here: https://doi.org/10.1136/bmjopen-2023-078713 Affiliated Lab Transplant Anesthesia Research Group Principal investigator UCSF Michael Bokoch, MD, PhD Associate Professor Mentors UCSF Matthieu Legrand, MD, PhD Visiting Professor Collaborators UCSF Dieter Adelmann, MD, PhD Associate Professor Rishi Kothari, MD Personal Services Contractor Support this research Are you excited by the innovative work we’re doing on this project? Learn how your financial support can make the difference in our work. Support
